Protocol Ledger

NCT07223593 · Phase III · RECRUITING

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

Interventional Phase III clinical trial protocol NCT07223593 sponsored by Eli Lilly and Company in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-10-31 Enrollment: 1,205 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07223593
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,205 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07223593
Protocol FieldVerified Registry Value
NCT IdentifierNCT07223593
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment1,205 participants (ESTIMATED)
Registered Start Date2025-10-31
WhyStopped ClassificationNot Stopped

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI